• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Harold Varmus joins the International Biomedical Research Alliance board

Harold Varmus joins the International Biomedical Research Alliance board

June 3, 2016
CenterWatch Staff

The International Biomedical Research Alliance, a nonprofit organization which provides programming and funding support for the National Institutes of Health (NIH) Oxford-Cambridge Scholars Program, has announced that Harold Varmus, M.D., is joining the Alliance’s board of directors.

Varmus, co-recipient of the Nobel Prize in Physiology or Medicine for discovering the cellular origin of retroviral oncogenes, stepped down as director of the National Cancer Institute (NCI) in 2015; previously, he served as president of Memorial Sloan-Kettering Cancer Center and as director of the NIH. He is currently the Lewis Thomas University Professor of Medicine at the Meyer Cancer Center of Weill Cornell Medical College in New York and a senior associate at the New York Genome Center.

“The International Biomedical Research Alliance’s goal is to help train a new generation of top biomedical researchers who are better equipped to investigate human diseases and develop new preventions, treatments, and cures,” said Stephen M. McLean, chairman of the Alliance board of directors. “We want to increase the speed at which medical research occurs and also the efficacy of outcomes for patients.”

Varmus has had a long association with the Scholars Program, has met with many of its students, and has said that he is joining the board “to promote the development of the scientific careers of these remarkably talented young people.”

The NIH Oxford-Cambridge Scholars Program was created in 2001, through collaboration between the NIH and Oxford and Cambridge Universities, to revolutionize the way in which the most talented biomedical Ph.D. and M.D./Ph.D. students in the U.S. and the European Union are taught. Participants in the Program receive accelerated training, work on collaborative projects that address critical biomedical research problems, and graduate approximately two years early with a Ph.D. degree from either Oxford or Cambridge University. They spend an equal amount of time with a mentor in a laboratory at either Oxford or Cambridge University and an NIH Intramural Laboratory.

“The NIH Oxford-Cambridge Scholars Program has exceeded our expectations in training the next generation of biomedical researchers and in fostering international research collaborations,” said Michael Gottesman, M.D., deputy director of intramural research at the NIH and chief of the Laboratory of Cell Biology at the NCI. “I can think of no one better than Harold Varmus to help the NIH-OxCam Program maintain its hallmark characteristics of intellectual freedom and flexibility that have made the program the success that it is.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing